JP2023139158A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023139158A5 JP2023139158A5 JP2023119000A JP2023119000A JP2023139158A5 JP 2023139158 A5 JP2023139158 A5 JP 2023139158A5 JP 2023119000 A JP2023119000 A JP 2023119000A JP 2023119000 A JP2023119000 A JP 2023119000A JP 2023139158 A5 JP2023139158 A5 JP 2023139158A5
- Authority
- JP
- Japan
- Prior art keywords
- pen
- lys
- phe
- seq
- nal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DTERQYGMUDWYAZ-UHFFFAOYSA-N N-acetyl-N-thioacetyl-Lysine Natural products CC(=O)NCCCCC(N)C(O)=O DTERQYGMUDWYAZ-UHFFFAOYSA-N 0.000 claims description 828
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 413
- 239000003112 inhibitor Substances 0.000 claims description 397
- 150000003839 salts Chemical class 0.000 claims description 230
- 150000001413 amino acids Chemical class 0.000 claims description 86
- 235000001014 amino acid Nutrition 0.000 claims description 61
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 60
- 235000004279 alanine Nutrition 0.000 claims description 50
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 30
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- -1 Ala Chemical compound 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 244000191761 Sida cordifolia Species 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 16
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 16
- DPDPQQHHTHKSRN-UHFFFAOYSA-N 4-aminooxane-4-carboxylic acid Chemical compound OC(=O)C1(N)CCOCC1 DPDPQQHHTHKSRN-UHFFFAOYSA-N 0.000 claims description 16
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 125000001475 halogen functional group Chemical group 0.000 claims description 11
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 8
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 150000003462 sulfoxides Chemical class 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 208000015943 Coeliac disease Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims description 6
- 101710195550 Interleukin-23 receptor Proteins 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 206010009887 colitis Diseases 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 102000013264 Interleukin-23 Human genes 0.000 claims description 4
- 108010065637 Interleukin-23 Proteins 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000002702 enteric coating Substances 0.000 claims description 4
- 238000009505 enteric coating Methods 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 229940124829 interleukin-23 Drugs 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000006850 spacer group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 3
- 208000031879 Chédiak-Higashi syndrome Diseases 0.000 claims description 3
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims description 3
- 208000005577 Gastroenteritis Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 208000011476 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib Diseases 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000002389 Pouchitis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 206010062164 Seronegative arthritis Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims description 3
- 230000003872 anastomosis Effects 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000003167 cholangitis Diseases 0.000 claims description 3
- 201000001352 cholecystitis Diseases 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 208000016532 chronic granulomatous disease Diseases 0.000 claims description 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 3
- 208000008609 collagenous colitis Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 208000037902 enteropathy Diseases 0.000 claims description 3
- 206010057271 eosinophilic colitis Diseases 0.000 claims description 3
- 208000005516 glycogen storage disease Ib Diseases 0.000 claims description 3
- 208000024908 graft versus host disease Diseases 0.000 claims description 3
- 230000015788 innate immune response Effects 0.000 claims description 3
- 208000028774 intestinal disease Diseases 0.000 claims description 3
- 201000008105 leukocyte adhesion deficiency 1 Diseases 0.000 claims description 3
- 208000004396 mastitis Diseases 0.000 claims description 3
- 208000008275 microscopic colitis Diseases 0.000 claims description 3
- 238000010880 proctocolectomy Methods 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- SNLOIIPRZGMRAB-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(1h-pyrrolo[2,3-b]pyridin-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H]([NH3+])C([O-])=O)=CNC2=N1 SNLOIIPRZGMRAB-QMMMGPOBSA-N 0.000 claims description 2
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical class CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- CDUUKBXTEOFITR-UHFFFAOYSA-N alpha-methylserine Natural products OCC([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical group NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062961624P | 2020-01-15 | 2020-01-15 | |
| US62/961,624 | 2020-01-15 | ||
| PCT/US2021/013463 WO2021146441A1 (en) | 2020-01-15 | 2021-01-14 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP2022543052A JP7441955B2 (ja) | 2020-01-15 | 2021-01-14 | インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022543052A Division JP7441955B2 (ja) | 2020-01-15 | 2021-01-14 | インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023139158A JP2023139158A (ja) | 2023-10-03 |
| JP2023139158A5 true JP2023139158A5 (enExample) | 2024-01-19 |
Family
ID=76864704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022543052A Active JP7441955B2 (ja) | 2020-01-15 | 2021-01-14 | インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用 |
| JP2023119000A Pending JP2023139158A (ja) | 2020-01-15 | 2023-07-21 | インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022543052A Active JP7441955B2 (ja) | 2020-01-15 | 2021-01-14 | インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用 |
Country Status (32)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2968443T3 (pl) | 2013-03-15 | 2022-02-07 | Protagonist Therapeutics, Inc. | Analogi hepcydyny i ich zastosowania |
| CN113621027A (zh) | 2014-05-16 | 2021-11-09 | 领导医疗有限公司 | α4β7整联蛋白硫醚肽拮抗剂 |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| JP7534382B2 (ja) * | 2019-07-10 | 2024-08-14 | プロタゴニスト セラピューティクス， インコーポレイテッド | インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 |
| CN118063554A (zh) | 2020-01-15 | 2024-05-24 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
| EP4090669A4 (en) | 2020-01-15 | 2024-11-20 | Janssen Biotech, Inc. | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES |
| EP4247403A4 (en) * | 2020-11-20 | 2024-12-11 | JANSSEN Pharmaceutica NV | COMPOSITIONS OF PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR |
| AU2022311814A1 (en) | 2021-07-14 | 2024-02-29 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| CN117999274A (zh) * | 2021-07-14 | 2024-05-07 | 詹森生物科技公司 | 白介素-23受体的肽抑制剂 |
| EP4373800A4 (en) * | 2021-07-23 | 2025-10-15 | Blackstone Therapeutics Llc | PROCESS FOR THE PREPARATION OF HEXAHYDROCANNABINOL |
| IL313185A (en) | 2021-12-01 | 2024-07-01 | Zealand Pharma As | Peptide inhibitors of the interleukin-23 receptor |
| PE20241895A1 (es) | 2022-02-01 | 2024-09-19 | Janssen Pharmaceutica Nv | Inhibidores peptidicos del receptor de interleucina-23 y composiciones farmaceuticas de estos |
| WO2023177452A1 (en) * | 2022-03-14 | 2023-09-21 | Colorado Chromatography, Llc | Hydrogenation of cannabigerol and cannabichromene |
| EP4547337A1 (en) | 2022-06-30 | 2025-05-07 | Sanofi | New peptides as selective il-23 receptor antagonists |
| KR20250110326A (ko) * | 2022-11-21 | 2025-07-18 | 얀센 파마슈티카 엔브이 | 고리형 펩타이드의 합성 |
| AU2023404553A1 (en) * | 2022-11-30 | 2025-07-10 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Polypeptide inhibitor, and preparation method therefor and use thereof |
| EP4652180A2 (en) * | 2023-01-16 | 2025-11-26 | Janssen Pharmaceutica NV | Peptide inhibitors of interleukin-23 receptor |
| WO2024155553A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Lipidated peptide inhibitors of interleukin-23 receptor |
| EP4652182A1 (en) * | 2023-01-16 | 2025-11-26 | Janssen Pharmaceutica NV | Peptide inhibitors of interleukin-23 receptor |
| AU2024214418A1 (en) | 2023-01-31 | 2025-09-18 | Janssen Pharmaceutica Nv | Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor |
| AU2024233524A1 (en) * | 2023-03-03 | 2025-10-16 | Janssen Pharmaceutica Nv | Interleukin-23 receptor antagonist peptides for use in the treatment of psoriasis |
| WO2024227437A1 (zh) * | 2023-05-04 | 2024-11-07 | 西藏海思科制药有限公司 | 白介素-23受体的肽抑制剂制备及其用途 |
| EP4471048A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471049A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2025051912A1 (en) * | 2023-09-08 | 2025-03-13 | Sanofi | New peptides as selective il-23 receptor inhibitors |
| WO2025163534A1 (en) | 2024-01-31 | 2025-08-07 | Janssen Pharmaceutica Nv | Crystal form of a peptide inhibitor of interleukin-23 receptor |
| WO2025243217A1 (en) * | 2024-05-22 | 2025-11-27 | Janssen Pharmaceutica Nv | Crystal forms of peptide molecules |
| CN120905324A (zh) * | 2025-10-10 | 2025-11-07 | 北京元延医药科技股份有限公司 | 白细胞介素-23受体肽抑制剂及其手性中间体的制法 |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| US4724229A (en) | 1986-09-30 | 1988-02-09 | Smithkline Beckman Corporation | Arg-arg-arg-vasopressin antagonists |
| JPH02306947A (ja) | 1989-05-01 | 1990-12-20 | Monsanto Co | キラルβ―アミノ酸の製造方法 |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| CA2106314A1 (en) | 1991-04-05 | 1992-10-06 | John P. Burnier | Platelet aggregation inhibitors having high specification for gpiibiiia |
| US5569741A (en) | 1992-07-27 | 1996-10-29 | Biomeasure, Inc. | Cyclic octapeptide neuromedin B receptor antagonists |
| DE69332826T2 (de) | 1992-11-12 | 2004-01-29 | Sod Conseils Rech Applic | Opioidpeptide |
| AU673731B2 (en) | 1993-06-03 | 1996-11-21 | Banyu Pharmaceutical Co., Ltd. | Novel endothelin antagonistic peptide |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US5990084A (en) | 1996-04-19 | 1999-11-23 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
| US7122623B2 (en) | 1996-07-12 | 2006-10-17 | Adherex Technologies, Inc. | Compounds and methods for modulating cell adhesion |
| CZ300837B6 (cs) | 1996-08-30 | 2009-08-26 | Novo Nordisk A/S | Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití |
| US5942492A (en) | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| US5993811A (en) | 1997-02-03 | 1999-11-30 | Biology Associates, Llc | Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis |
| AU8399998A (en) | 1997-07-11 | 1999-02-08 | Innerdyne, Inc. | Methods and systems for preparing and sealing radiation delivery structures |
| US6818617B1 (en) | 1997-08-15 | 2004-11-16 | Temple University- Of The Commonwealth System Of Higher Education | EC-3, an inhibitor of α4β1 and α4β7 integrins |
| AU750175B2 (en) | 1997-11-24 | 2002-07-11 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
| US8038984B2 (en) | 1998-06-20 | 2011-10-18 | Washington University | Membrane-permeant peptide complexes for treatment of sepsis |
| US6248057B1 (en) | 1998-07-28 | 2001-06-19 | Innerdyne, Inc. | Absorbable brachytherapy and chemotherapy delivery devices and methods |
| AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| AUPP616498A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Synthesis of cyclic peptides |
| AUPP616598A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Auxiliary for amide bond formation |
| AUPP660698A0 (en) | 1998-10-21 | 1998-11-12 | University Of Queensland, The | A method of protein engineering |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| PL351326A1 (en) | 1999-03-17 | 2003-04-07 | Novo Nordisk As | Method for acylating peptides and novel acylating agents |
| SK14372001A3 (sk) | 1999-04-12 | 2002-06-04 | Aventis Pharma Limited | Substituované bicyklické heteroarylové zlúčeniny ako antagonisty integrínu a farmaceutický prostriedok, ktorý ich obsahuje |
| WO2001068586A2 (en) | 2000-03-14 | 2001-09-20 | Novartis Ag | α4β1 AND α4β7 INTEGRIN INHIBITORS |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| WO2002055106A2 (en) | 2001-01-09 | 2002-07-18 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| DE10107707A1 (de) | 2001-02-19 | 2002-08-29 | Wilex Biotechnology Gmbh | Antagonisten für alpha¶4¶beta¶7¶-Integrin |
| AUPS039702A0 (en) | 2002-02-08 | 2002-03-07 | University Of Queensland, The | Common protein surface shapes and uses therefor |
| US20030166138A1 (en) | 2002-02-21 | 2003-09-04 | Todd Kinsella | Cyclic peptides and analogs useful to treat allergies |
| WO2004011650A2 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
| AU2003301059A1 (en) | 2002-12-18 | 2004-07-22 | Wyeth | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
| US20070032417A1 (en) | 2002-12-24 | 2007-02-08 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| CA2522680A1 (en) | 2003-04-15 | 2004-10-28 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
| DK2332968T3 (en) | 2003-11-05 | 2016-08-22 | Dana Farber Cancer Inst Inc | Alpha-helix peptides suitable for activating or inhibiting cell death |
| WO2005064345A2 (en) | 2003-12-19 | 2005-07-14 | Applera Corporation | Methods and systems for protein and peptide evidence assembly |
| NZ548702A (en) | 2004-01-09 | 2009-06-26 | Pfizer | Antibodies to MAdCAM |
| US8536140B2 (en) | 2004-03-12 | 2013-09-17 | Mti Meta Tech Inc. | Methods for treating inflammatory bowel disease |
| JP2008504239A (ja) | 2004-06-24 | 2008-02-14 | ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | 複合体およびその治療的使用 |
| WO2006032104A1 (en) | 2004-09-23 | 2006-03-30 | The University Of Melbourne | Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection |
| WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| US20080300180A1 (en) | 2004-11-30 | 2008-12-04 | Gastrotech Pharma A/S | Growth Hormone Secretagogue Receptor 1A Ligands |
| US20100183617A1 (en) | 2005-02-23 | 2010-07-22 | University Of Virginia Patent Foundation | Compositions and methods for regulating sas1r |
| US7534764B2 (en) | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
| CA2622441A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| EP2016177A2 (en) | 2006-04-12 | 2009-01-21 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
| GB0610395D0 (en) | 2006-05-25 | 2006-07-05 | Ge Healthcare Ltd | Novel imaging agents |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| US20080019913A1 (en) | 2006-07-07 | 2008-01-24 | University Of Arizona Office Of Technology Transfer | Enkepahlin analogs with improved bioavailability |
| KR101399175B1 (ko) | 2006-07-21 | 2014-06-19 | 푼다싸웅 지 앙빠루 아 뻬스끼자 두 에스따두 지 싸웅 파울루 - 에피아뻬에에씨뻬 | 항염증성 및 항알레르기성 시클릭 펩티드 |
| WO2008045252A2 (en) | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
| EP2109480B1 (en) | 2006-12-07 | 2017-06-28 | The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services | Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin |
| MX2009008104A (es) | 2007-02-02 | 2009-08-07 | Amgen Inc | Hepcidina, antagonistas de hepcidina y metodos de uso. |
| BRPI0807728A2 (pt) | 2007-02-15 | 2012-04-17 | Univ Indiana Res & Tech Corp | co-agonistas de receptor glucagon/glp-1 |
| SI2426144T1 (sl) | 2007-02-23 | 2019-02-28 | Merck Sharp & Dohme Corp. | Umetno proizvedena anti-IL23P19 antitelesa |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| EP2150564A2 (en) | 2007-04-27 | 2010-02-10 | ZymoGenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
| US8313950B2 (en) | 2007-05-21 | 2012-11-20 | The Ohio State University Research Foundation | Hepcidins as biomarkers for impending lupus nephritis flare |
| US20090131317A1 (en) | 2007-06-22 | 2009-05-21 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
| AU2008273814A1 (en) | 2007-07-06 | 2009-01-15 | Valorisation Hsj, Societe En Commandite | IL-23 receptor antagonists and uses thereof |
| CN101358201A (zh) | 2007-07-31 | 2009-02-04 | 钱忠明 | 重组人铁调素腺病毒、其制备方法及应用 |
| CN101307085B (zh) | 2007-08-01 | 2012-06-13 | 香港理工大学深圳研究院 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| GR1006896B (el) | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
| WO2009039185A1 (en) | 2007-09-17 | 2009-03-26 | The Trustees Of Columbia University In The City Of New York | Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation |
| WO2009045536A2 (en) | 2007-10-05 | 2009-04-09 | The University Of North Carolina At Chapel Hill | Receptor targeted oligonucleotides |
| CA2741566A1 (en) | 2008-11-03 | 2010-06-03 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| US8435941B2 (en) | 2008-12-05 | 2013-05-07 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
| DE102009007381A1 (de) | 2009-01-29 | 2010-08-05 | Amp-Therapeutics Gmbh & Co. Kg | Antibiotische Peptide |
| US8999935B2 (en) | 2009-02-11 | 2015-04-07 | New York University | Treatment of osteoporosis in peri- and post-menopausal women with hepcidin |
| US9175037B2 (en) | 2009-04-08 | 2015-11-03 | Takeda Pharmaceutical Company Limited | Neuromedin U derivative |
| TWI578992B (zh) | 2009-04-30 | 2017-04-21 | 諾克森製藥股份有限公司 | 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類 |
| US20110142889A1 (en) | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| EP2528934A4 (en) | 2010-01-25 | 2013-08-21 | Univ Cornell | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF |
| US10416172B2 (en) | 2010-03-31 | 2019-09-17 | Medical Diagnostic Laboratories, Llc | Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling |
| JP2011231085A (ja) | 2010-04-30 | 2011-11-17 | Osaka Prefecture Univ | 環状ペプチド |
| WO2011149942A2 (en) | 2010-05-24 | 2011-12-01 | Children's Medical Center Corporation | Compositions and methods for plasma peptide analysis |
| IT1406051B1 (it) | 2010-08-05 | 2014-02-06 | D M G Italia S R L | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. |
| CA3040415A1 (en) | 2010-08-11 | 2012-02-16 | Forest Laboratories Holdings Limited | Stable formulations of linaclotide |
| EP2444101A1 (en) | 2010-10-21 | 2012-04-25 | Universitätsklinikum Freiburg | Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis |
| US9243034B2 (en) | 2011-01-27 | 2016-01-26 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
| US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US9605027B2 (en) | 2011-06-14 | 2017-03-28 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| HK1197028A1 (en) | 2011-06-14 | 2015-01-02 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| US9169292B2 (en) | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| EP2788370B1 (en) | 2011-12-09 | 2020-02-05 | The Regents of The University of California | Modified mini-hepcidin peptides and methods of using thereof |
| US20150157692A1 (en) | 2012-05-23 | 2015-06-11 | The University Of Chicago | Methods of treating obesity |
| US9024044B2 (en) | 2012-06-14 | 2015-05-05 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| WO2014127316A2 (en) | 2013-02-15 | 2014-08-21 | Srx Cardio, Llc | Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels |
| PL2968443T3 (pl) | 2013-03-15 | 2022-02-07 | Protagonist Therapeutics, Inc. | Analogi hepcydyny i ich zastosowania |
| US20140294902A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide antagonists |
| US20140294901A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide dimer antagonists |
| DK3013351T3 (da) | 2013-06-24 | 2020-01-27 | Canbas Co Ltd | Peptider og peptidmimetika i kombinationanvendelser og behandlinger til cancerpatient-subpopulationer |
| CA2916492A1 (en) | 2013-06-27 | 2014-12-31 | Stealth Biotherapeutics Corp | Peptide therapeutics and methods for using same |
| CA2926685A1 (en) | 2013-10-09 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| US9284362B2 (en) | 2014-01-22 | 2016-03-15 | Wisconsin Alumni Research Foundation | α/β-peptide mimics of Z-domain peptides |
| US9315545B2 (en) | 2014-04-07 | 2016-04-19 | Merganser Biotech, Inc. | Hepcidin mimetic peptides and uses thereof |
| CN113621027A (zh) | 2014-05-16 | 2021-11-09 | 领导医疗有限公司 | α4β7整联蛋白硫醚肽拮抗剂 |
| WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| AU2015279571A1 (en) | 2014-06-27 | 2017-02-02 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
| WO2016004093A2 (en) | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| AU2015328002A1 (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics, Inc. | Novel alpha4beta7 peptide monomer and dimer antagonists |
| JP2018508466A (ja) | 2014-12-29 | 2018-03-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｓ−アルキル化ヘプシジンペプチドならびにその作製及び使用方法 |
| US20160199437A1 (en) | 2015-01-08 | 2016-07-14 | D. Travis Wilson | Therapeutic compositions including iron chelators and uses thereof |
| US20170369871A1 (en) | 2015-01-12 | 2017-12-28 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
| US20160228491A1 (en) | 2015-02-09 | 2016-08-11 | Stealth Biotherapeutics Corp | Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof |
| WO2016195663A1 (en) | 2015-06-02 | 2016-12-08 | Stealth Peptides International, Inc. | Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof |
| WO2016200364A1 (en) | 2015-06-08 | 2016-12-15 | Stealth Peptides International, Inc. | THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF |
| SG10201912066SA (en) | 2015-07-15 | 2020-02-27 | Protagonist Therapeutics Inc | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| EP3432906A4 (en) | 2016-03-23 | 2020-04-01 | Protagonist Therapeutics, Inc. | METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS |
| WO2018022917A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Disulfide-rich peptide libraries and methods of use thereof |
| US20190270786A1 (en) | 2016-07-27 | 2019-09-05 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| US20200064357A1 (en) | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| AU2017371472B2 (en) | 2016-12-06 | 2024-08-08 | Universiteit Van Amsterdam | Multicyclic peptides and methods for their preparation |
| WO2018136646A1 (en) * | 2017-01-18 | 2018-07-26 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| TW201920234A (zh) | 2017-09-11 | 2019-06-01 | 美商領導醫療有限公司 | 類鴉片促效劑肽及其用途 |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP3810094A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| JOP20190150A1 (ar) | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
| EP3820883A4 (en) | 2018-07-12 | 2022-04-20 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AU2020244884A1 (en) | 2019-03-28 | 2021-11-18 | Protagonist Therapeutics, Inc. | Methods for synthesizing β-homoamino acids |
| JP7534382B2 (ja) | 2019-07-10 | 2024-08-14 | プロタゴニスト セラピューティクス， インコーポレイテッド | インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 |
| TW202116793A (zh) | 2019-07-10 | 2021-05-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其於治療發炎疾病的用途 |
| US20220372099A1 (en) | 2019-09-03 | 2022-11-24 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| AU2021205415A1 (en) | 2020-01-10 | 2022-07-21 | Protagonist Therapeutics, Inc. | Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists |
| CN118063554A (zh) * | 2020-01-15 | 2024-05-24 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
| EP4090669A4 (en) | 2020-01-15 | 2024-11-20 | Janssen Biotech, Inc. | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES |
| WO2021146458A1 (en) | 2020-01-15 | 2021-07-22 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US20240018189A1 (en) | 2020-07-28 | 2024-01-18 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP4247403A4 (en) | 2020-11-20 | 2024-12-11 | JANSSEN Pharmaceutica NV | COMPOSITIONS OF PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR |
| US20240226225A1 (en) | 2021-04-01 | 2024-07-11 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| WO2022212696A1 (en) | 2021-04-01 | 2022-10-06 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP4355763A4 (en) | 2021-06-14 | 2025-07-30 | Protagonist Therapeutics Inc | HEPCIDIN MIMETICS FOR THE TREATMENT OF HEREDITARY HEMOCHROMATOSIS |
-
2021
- 2021-01-14 CN CN202410241029.2A patent/CN118063554A/zh active Pending
- 2021-01-14 HU HUE21741383A patent/HUE072238T2/hu unknown
- 2021-01-14 TW TW110101518A patent/TWI882061B/zh active
- 2021-01-14 CN CN202410241160.9A patent/CN118005737A/zh active Pending
- 2021-01-14 LT LTEPPCT/US2021/013463T patent/LT4090670T/lt unknown
- 2021-01-14 EP EP21741383.0A patent/EP4090670B1/en active Active
- 2021-01-14 HR HRP20250769TT patent/HRP20250769T1/hr unknown
- 2021-01-14 SM SM20250254T patent/SMT202500254T1/it unknown
- 2021-01-14 FI FIEP21741383.0T patent/FI4090670T3/fi active
- 2021-01-14 AU AU2021207653A patent/AU2021207653A1/en active Pending
- 2021-01-14 SI SI202130323T patent/SI4090670T1/sl unknown
- 2021-01-14 JO JOP/2022/0169A patent/JOP20220169A1/ar unknown
- 2021-01-14 US US17/149,509 patent/US11845808B2/en active Active
- 2021-01-14 CA CA3167751A patent/CA3167751A1/en active Pending
- 2021-01-14 PE PE2022001452A patent/PE20230370A1/es unknown
- 2021-01-14 ES ES21741383T patent/ES3036287T3/es active Active
- 2021-01-14 MX MX2022008741A patent/MX2022008741A/es unknown
- 2021-01-14 KR KR1020227028050A patent/KR20220141807A/ko active Pending
- 2021-01-14 MA MA58373A patent/MA58373B1/fr unknown
- 2021-01-14 RS RS20250644A patent/RS66991B1/sr unknown
- 2021-01-14 JP JP2022543052A patent/JP7441955B2/ja active Active
- 2021-01-14 WO PCT/US2021/013463 patent/WO2021146441A1/en not_active Ceased
- 2021-01-14 PT PT217413830T patent/PT4090670T/pt unknown
- 2021-01-14 PL PL21741383.0T patent/PL4090670T3/pl unknown
- 2021-01-14 DK DK21741383.0T patent/DK4090670T3/da active
- 2021-01-14 CR CR20220332A patent/CR20220332A/es unknown
- 2021-01-14 PH PH1/2022/551750A patent/PH12022551750A1/en unknown
- 2021-01-14 CN CN202180021374.XA patent/CN115298196A/zh active Pending
- 2021-01-14 TW TW113150722A patent/TW202515892A/zh unknown
- 2021-01-14 CN CN202410241008.0A patent/CN118005736A/zh active Pending
- 2021-01-14 IL IL294680A patent/IL294680A/en unknown
- 2021-01-14 CN CN202410241221.1A patent/CN118027153A/zh active Pending
- 2021-01-14 EP EP25180267.4A patent/EP4613761A2/en active Pending
- 2021-01-15 AR ARP210100106A patent/AR121070A1/es unknown
-
2022
- 2022-07-13 CL CL2022001893A patent/CL2022001893A1/es unknown
- 2022-07-14 DO DO2022000147A patent/DOP2022000147A/es unknown
- 2022-07-14 CO CONC2022/0009931A patent/CO2022009931A2/es unknown
- 2022-08-11 EC ECSENADI202263238A patent/ECSP22063238A/es unknown
-
2023
- 2023-07-21 JP JP2023119000A patent/JP2023139158A/ja active Pending
- 2023-10-23 US US18/492,612 patent/US20240150405A1/en active Pending
-
2024
- 2024-12-26 CL CL2024004039A patent/CL2024004039A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023139158A5 (enExample) | ||
| JPWO2021146441A5 (enExample) | ||
| JP2025134806A5 (enExample) | ||
| JPWO2020014646A5 (enExample) | ||
| ES2626390T3 (es) | Moduladores del receptor gamma huérfano relacionado con retinoide (ROR-gamma) para uso en el tratamiento de enfermedades autoinmunitarias e inflamatorias | |
| JP2017530090A5 (enExample) | ||
| TW201041866A (en) | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | |
| CN105121443B (zh) | 蛋白激酶抑制剂 | |
| JPWO2021146454A5 (enExample) | ||
| AU2022340959A1 (en) | Synthesis of bicycle toxin conjugates, and intermediates thereof | |
| JP2020505352A5 (enExample) | ||
| HUP0301801A2 (hu) | Imidazo[1,2-a]pirazin-származékok és az ezeket tartalmazó gyógyszerkészítmények | |
| WO2019191166A1 (en) | Hepatitis b antiviral agents | |
| HU229481B1 (hu) | Helyettesített imidazolidin-származékok, eljárás elõállításukra, alkalmazásuk, valamint hatóanyagként ezeket tartalmazó gyógyszerkészítmények | |
| JP2015533833A5 (enExample) | ||
| AU2009257631A1 (en) | Melanocortin receptor-specific peptides for treatment of sexual dysfunction | |
| JP5067364B2 (ja) | アシルアミノピペリジン化合物 | |
| CN102239172A (zh) | Hiv整合酶抑制剂 | |
| JP2012524775A5 (enExample) | ||
| CN104302642A (zh) | 制备新的苯并咪唑衍生物的方法 | |
| TW202214619A (zh) | 苯并咪唑類衍生物、其製備方法及醫藥用途 | |
| CN119136796A (zh) | 靶向神经降压素受体的化合物和放射性配体及其用途 | |
| JPWO2012053630A1 (ja) | 変異アンドロゲン受容体拮抗薬 | |
| CN105254630A (zh) | 一种阿哌沙班的制备方法 | |
| CN109320590B (zh) | 抗生素teixobactin及其类似物的合成路线 |